U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, providing a new treatment option in front-line GEA Second FDA approval for zanidatamab in less than two years further validates Zymeworks’ proprietary Azymetric™ bispecific antibody platform and internal discovery engine FDA approval […]
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- FDA approves Jazz's Ziihera in frontline gastric cancer endpoints.news
- Jazz wins FDA nod for cancer therapy developed with BeOne, Zymeworks seekingalpha.com
- FDA approves Tevimbra combo for HER2+ gastric cancer treatment investing.com
